N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Sponsor: UNC Lineberger Comprehensive Cancer Center • ClinicalTrials.gov ID: NCT07340541

Registry updated: 2026-09-18
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patients with estrogen receptor-positive/hormone receptor-negative (ER+/HR-) and triple-negative (TN) metastatic breast cancer (MBC). The trial integrates both retrospective and prospective data collection, including archival tumor tissue, medical record abstraction, and prospective tumor and blood sampling prior to initiation of protocol directed treatment. Based on biomarker subtype, participants will receive standard of care therapy. Liquid biopsy will be collected on Cycle 2 Day 1, and then liquid biopsy, imaging and clinical data will be collected at each re-staging. Treatment will continue until discontinuation for progression, toxicity or at the discretion of the treating physician.

Interventions

  • SERD* + abemaciclib (Drug)
    Investigators choice Selective Estrogen Receptor Degrader + abemaciclib therapy.
  • SERD* + everolimus (Drug)
    Investigators choice Selective Estrogen Receptor Degrader + everolimus therapy.
  • SERD* + everolimus or capecitabine (Drug)
    Investigators choice Selective Estrogen Receptor Degrader + everolimus or capecitabine therapy.
  • SOC (Drug)
    standard-of-care (SOC) chemotherapy in breast cancer
  • Antiandrogen (Drug)
    Antiandrogen therapy

Eligibility criteria

Inclusion Criteria: * Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. * Subject is willing and able to comply with study procedures based on the judgement of the investigator. * Age ≥ 18 years of age at the time of consent * ECOG Performance Status of 0-2 (see APPENDIX A: ECOG Performance Status Scale). * Patients must fulfill all eligibility criteria outlined in the LCCC2521 Parent Protocol and consented to LCCC2521 Parent Protocol Exclusion Criteria: * Inaccessible metastatic lesion to research biopsy * Subject has already initiated 2nd line therapy * Concurrent disease or condition that in the opinion of the treating oncologist renders the patient inappropriate for study participation

Conditions

Breast Cancer Metastatic Breast Cancer Triple Negative Breast Cancer Estrogen-receptor-positive Breast Cancer Hormone Receptor Negative Breast Carcinoma

Locations

  • Yale Cancer Center Clinical Trials Office — New Haven, Connecticut, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland, United States
  • Mayo Clinic — Rochester, Minnesota, United States
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill — Chapel Hill, North Carolina, United States
  • University of Pennsylvania/Abramson Cancer Center — Philadelphia, Pennsylvania, United States
  • Baylor College of Medicine — Houston, Texas, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record